### UNDERSTANDING AND INTERPRETATION OF THE GLOBAL BURDEN OF DISEASE (GBD) STUDY ESTIMATES ON NEUROLOGICAL DISORDERS

#### Prof. Valery Feigin

National Institute for Stroke & Applied Neurosciences Faculty of Health and Environmental Sciences Auckland University of Technology, New Zealand

18 October 14:45-16:15, Room Hall 520BE



XXVI WORLD CONGRESS OF NEUROLOGY



# Disclosure

- Chair (unpaid) International Advisory Committee of the SAMURAI Study
- Travel support from Moleac Pte Ltd

### **Evolving GBD coverage of neurological conditions**



## **GBD** Neurological Collaboration 2021

### 102 countries, 1750 collaborators



### **21 GBD REGIONS AND 7 SUPER-REGIONS**



Subnational estimates available for 20 countries:

• USA

non- Māori)

- Brazil
- Iran
  - India
  - Pakistan
  - Indonesia
  - Philippines
  - Ethiopia
  - Kenya
  - South Africa
  - Nigeria
- Mexico

### GLOBAL, REGIONAL, AND NATIONAL BURDEN OF DISORDERS AFFECTING THE NERVOUS SYSTEM, 1990-2021:

a systematic analysis of the Global Burden of Disease Study 2021. Lancet Neurology 2023



#### 36 disease and injury outcomes

15 previous + neurodevelopmental conditions in children (attentiondeficit/hyperactivity disorder, autism spectrum disorders, foetal alcohol syndrome, idiopathic developmental intellectual disability, neonatal encephalopathy, neural tube defects, congenital birth defects, Klinefelter syndrome, preterm birth, Down syndrome, other chromosomal abnormalities) and additional often disabling CNS infections and other conditions (COVID-19, Zika congenital, syphilis, neonatal sepsis, malaria, neonatal jaundice, rabies)



### All available (1990-2021) data sources

population-representative studies, large-scale surveys, censuses, insurance claims, and hospital records that catalogue incidence and prevalence for each condition (36,000+ incidence, prevalence and other studies for non-fatal models; vital data from ICD-9 and ICD-10 codes, verbal autopsy, registry and MoH and other admin data for mortality estimates of 14 fatal conditions)

THE GBD STUDY 2021 NEUROLOGY COLLABORATION GROUP

#### PAF of disease DALYs



expected decrease in DALYs (YLDs + YLLs) if risk exposure had equalled the theoretical minimum risk exposure level [TMREL] (regression analysis)

#### Comorbidity correction



## Stor.

#### Analysis

by age, sex, 21 GBD regions, 204 countries (Dismod-MR 2.1 regression analysis for nonfatal estimates; ensemble modeling approach to fatal estimates)



## **SELECTION**

of 36 neurological conditions for GBD 2021

- 1. Alzheimer's disease and other dementias
- 2. Attention-deficit/hyperactivity disorder
- 3. Autism spectrum disorders
- 4. Encephalitis+
- 5. Foetal alcohol syndrome
- 6. Guillain-Barré syndrome+
- 7. Headache disorders (migraine, tension-type)
- 8. Idiopathic epilepsy<sup>+</sup>
- 9. Idiopathic developmental intellectual disability
- 10. Meningitis<sup>+</sup>
- 11. Motor neuron disease<sup>+</sup>
- 12. Multiple sclerosis<sup>+</sup>

- 13. Neonatal encephalopathy<sup>+</sup>
- 14. Neural tube defects<sup>+</sup>
- 15. Nervous system cancer (central nervous system;
- 16. Neuroblastoma and other peripheral nervous cell tumours)<sup>+</sup>
- 17. Neurocysticercosis
- 18. Other neurological disorders<sup>+</sup>
- 19. Parkinson's disease<sup>+</sup>
- 20. Traumatic brain injury
- 21. Rabies<sup>+</sup>
- 22. Spinal cord injury
- 23. Stroke (ischaemic stroke, subarachnoid haemorrhage, intracerebral haemorrhage)<sup>†</sup>
- 24. Tetanus†

- 25. Congenital birth defect
- 26. COVID-19
- 27. Down syndrome
- 28. Echinococcosis (cystic)
- 29. Klinefelter syndrome
- 30. Malaria
- 31. Neonatal jaundice
- 32. Neonatal sepsis
- Other chromosomal abnormalities
- 34. Preterm birth
- 35. Syphilis (congenital and adult neurosyphilis)
- 36. Zika virus disease (congenital)

### 12 conditions with neurological features

THE GBD STUDY 2021 NEUROLOGY COLLABORATION GROUP

## CONDITIONS

in other neurological disorders category

#### ICD-9\*

- Cerebral degenerations usually manifest in childhood
- Idiopathic normal pressure hydrocephalus
- Corticobasal degeneration
- Cerebral degeneration in diseases classified elsewhere
- Other cerebral degeneration or unspecified
- Other extrapyramidal disease and abnormal movement disorders
- Spinocerebellar disease
- Other diseases of spinal cord
- Disorders of the autonomic nervous system
- Other demyelinating diseases of

central nervous system

- Other and unspecified disorders of the nervous system
- Other or unspecified nerve root and plexus disorders
- Hereditary and idiopathic peripheral neuropathy
- Acute infective polyneuritis
- Polyneuropathy; myoneural disorders (eg, myasthenia gravis, lambert-eaton syndrome)
- Muscular dystrophies and other myopathies
- Neonatal myasthenia gravis

- Dementia in other diseases classified elsewhere
- Huntington's disease
- hereditary ataxia
- spinal muscular atrophy and related syndromes
- systemic atrophies primarily affecting central nervous system in diseases classified elsewhere
- other degenerative diseases of basal ganglia
- dystonia
- other extrapyramidal and movement disorders
- extrapyramidal and movement disorders in diseases classified

#### elsewhere

**ICD-10\*** 

- other demyelinating diseases of central nervous system
- inflammatory polyneuropathy (includes fatal outcomes of Guillain-Barré syndrome)
- myasthenia gravis and other myoneural disorders
- primary disorders of muscles (eg, muscular dystrophy)
- disorders of myoneural junction and muscle in diseases classified elsewhere

\* — Listed conditions correspond to three-digit ICD coding unless four-digit is required to code to an included neurological category

THE GBD STUDY 2021 NEUROLOGY COLLABORATION GROUP

### Conditions in other neurological disorders category

• \*Listed conditions correspond to three-digit ICD coding unless four-digit is required to code to an included neurological category

### ICD-9\*

Cerebral degenerations usually manifest in childhood; idiopathic normal pressure hydrocephalus; corticobasal degeneration; cerebral degeneration in diseases classified elsewhere; other cerebral degeneration or unspecified; other extrapyramidal disease and abnormal movement disorders; spinocerebellar disease; other diseases of spinal cord; disorders of the autonomic nervous system; other demyelinating diseases of central nervous system; other and unspecified disorders of the nervous system; other or unspecified nerve root and plexus disorders; hereditary and idiopathic peripheral neuropathy; acute infective polyneuritis; polyneuropathy; myoneural disorders (eg, myasthenia gravis, Lambert-Eaton syndrome); muscular dystrophies and other myopathies; neonatal myasthenia gravis

#### ICD-10\*

Dementia in other diseases classified elsewhere; Huntington's disease; hereditary ataxia; spinal muscular atrophy and related syndromes; systemic atrophies primarily affecting central nervous system in diseases classified elsewhere; other degenerative diseases of basal ganglia; dystonia; other extrapyramidal and movement disorders; extrapyramidal and movement disorders in diseases classified elsewhere; other demyelinating diseases of central nervous system; inflammatory polyneuropathy (includes fatal outcomes of Guillain-Barré syndrome); myasthenia gravis and other myoneural disorders; primary disorders of muscles (e.g., muscular dystrophy); disorders of myoneural junction and muscle in diseases classified elsewhere

## Principles of selection



## ICD-9 and ICD-10 (fatal) coding for each condition

Condition	ICD-9	ICD-10
Alzheimer's disease and other dementias	290, 291.2, 291.8, 294, 331	F00, F01, F02, F03, G30, G31
Encephalitis	062, 064.9, 139.0, 323	A83-A86.4, B94.1, F07.1, G04-G05.8; G21.3
Idiopathic epilepsy	345	G40, G41
Meningitis	036, 047, 049.9, 320.0-320.3; 320.5-320.89, 321-322.9	A39, A87, D86.81, G00, G03
Motor neuron disease	335	G12
Multiple sclerosis	340	G35
Neonatal encephalopathy due to birth asphyxia and trauma	761.7-761.9, 762, 763, 767, 768; 768.2-768.7, 768.9, 770.1 779.0-779.2	,P01.7, P02, P03, P10, P11, P12, P13, P14, P15, P20, P21, P24, P91
Nervous system cancers*		, C47, C47.0, C47.1, C47.10. C47.11, C47.12, C47.2, C47.20, C47.21, C47.22, C47.3, C47.4; C47.5, C47.6, C47.8; C47.9, C47.90, C70, C70.0, C70.1; C70.5, C70.6, C70.9, C71, C71.0, C71.1; C71.2, C71.3, C71.4, C71.5, C71.6; C71.7, C71.8, C71.9, C72, C72.0, C72.1; C72.2, C72.20, C72.21, C72.22, C72.3, C72.30, C72.31, C72.32, C72.4, C72.40, C72.41, C72.42, C72.5, C72.50, C72.59; C72.8, C72.9, C74 <sup>‡</sup> , C75.1-C75.3
Neural tube defects	740, 741, 742.0	Q00.0-Q00.2; Q01, Q05
Other neurological disorders	330, 331.8, 331.9, 333, 334, 335.3; 336, 337, 341, 349, 349.2, 349.3; 349.8, 353.8, 353.9, 356, 357.0, 357.1, 357.3, 357.4, 357.7, 358; 359, 775.2	F02.2, G10, G11, G12, G12.0, G12.1, G13, G23, G24, G25, G26, G26.0, G36, G37, G61, G70, G71, G73, G90, G95
Parkinson's disease	332, 332.0	F02.3, G20
Rabies	071	A82
Stroke (ischaemic)	433, 434, 435, 437	G45, G46, I63, I65, I66, I67.2-I67.6; 67.5-I67.6, I69.3
Stroke (intracerebral hemorrhage)	431, 432, 437.2	161, 162, 168.1-168.2, 169.1-169.2
Stroke (subarachnoid hemorrhage)	430	160, 162.0, 167.0-167.1, 169.0
Tetanus	037-037.9, 771.3, V03.7	A33, A34, A35



from 1990 to 2021

Data source	How it is used in the GBD
Census or population registry	Denominator, GDP
Vital registration/statistics or sample registration	——————————————————————————————————————
Demographic surveillance system	Causes of death
Verbal autopsies	Causes of death
Hospital and Ministry of Health data, WHO databases	Disease incidence and prevalence
Health insurance data	Disease incidence and prevalence
Surveys and disease registries	Incidence, prevalence, risk factors
Morbidity notification data and police records about notifiable infectious diseases or conditions (homicides, injuries etc)	Incidence, prevalence
Published literature (including 'grey' literature) from all possible sources, including PubMed, Scopus etc.	Disease incidence, prevalence, outcomes and risk factors

### Data sources

http://ghdx.healthdata.org/

IHME   GHDx   GBD Compare		Search
🔍 IHME   GHDX		Global Health Data Excha Discover the World's Healt
Home Countries Series and Systems Organizations	Keywords IHME Data About the GHDx	Help
In December 2022, IHME paused its COVID-19 modeling. Past estimates and 0	COVID-related resources remain publicly available via hea	althdata.org/covid.
Global Health Data Exchange		Recent IHME Datasets
Welcome to the GHDx, the world's most comprehensive catalog of surveys, cer It's the place to start your health data search. Learn more about the catalog in $\underline{G}$		WHO Americas Region Bacterial Antimicrot Resistance Burden Estimates 2019
<u>GBD 2019 data</u> <u>All IHME data</u>		Nigeria DTP Vaccine Coverage Estimates 20 2018
Data made available for download by IHME can be used, shared, modified, or b with the <u>IHME FREE-OF-CHARGE NON-COMMERCIAL USER AGREEMENT</u> commercial use), visit IHME <u>Terms and Conditions</u> .		United States Maternal Mortality Ratio Estim by Race and Ethnicity 1999-2019
Search Data Countr	ies	United States Stomach Cancer Mortality Ra County, Race, and Ethnicity 2000-2019
Afghani Advanced search >>> Search ?	stan 🔹	United States Mortality Rates by Causes of I and Life Expectancy by County, Race, and Ethnicity 2000-2019
More Ways to Explore the GHDx		Global Burden of Disease Study 2021 (GBD Sickle Cell Disease Birth Incidence, Prevale and Mortality 2000-2021
By Data Type     By Keyword     By Organization		View all Subscribe
<u>By Survey Family, Series or Systems</u>		Resources
		<ul> <li><u>Contact Us</u></li> <li><u>Data Sites We Love</u></li> <li><u>IHME Data Visualizations</u> @</li> </ul>

© 2023 University of Wash

# Understanding of basic GBD metrics

• Incidence: The number of new cases of a given cause during a given period in a specified population. In GBD, incidence rate is the rate per 100,000 population per year.

New cases of a disease (nominator) for 1 year / Population (denominator) x 100,000



# Understanding of basic GBD metrics

• **Prevalence**: The number of cases of a condition that are present in a specified population at a given time. In GBD, prevalence is the proportion cases of a condition per 100,000 population.

All alive cases of a disease (nominator) at a given time / Population (denominator) x 100,000



## Age-standardised

VS

## non-standardised rates

Age-standardisation allows comparisons between locations/countries by statistically transforming the age structure of a population to match that of a reference group. In this way, it is possible to adjust for the confounding effects of differences between the populations compared and over time. GBD uses a study-specific set of population weights that were originally derived from the World Health Organization standard and then refined over time to create the GBD population.



# Neurological disorders global age-specific burden in 2021: DALYs counts and rates



### Age-standardised estimates

Age-specific incidence		Age-specific proportion (%)		Calculating age-specific	
in your population per		of the standard (e.g., World)		incidence rates	weighted
100,000 people		population of the same		by the star	ndard:
per year:		age group	s (weights):		
35-44 2	20	35-44	12%	35-44 20 x 1	2 = 240
45-54 3	30	45-54	11%	45-54 30 x 1	1 = 330
55-64 4	40	55-64	8%	55-64 40 x 8	3 = 320
		Total:	31%	Total:	890

Age-standardised rate for your population of 35-64 years = 890/**31** = 28.7 per 100 000 population

## Neurological disorders global burden trends, 1990-2021: DALYs counts and rates by sex



## Understanding of basic GBD metrics

- Sequela: A complication of a neurological condition; the level of severity of a condition; health state (e.g., dead/alive)
- 95% Uncertainty Interval (UI): A range of values that reflects the certainty of an estimate. Larger uncertainty intervals can result from limited data availability, small studies and conflicting data, while smaller uncertainty intervals can result from extensive data availability, large studies and consistent data across different sources.

## Understanding of basic GBD metrics

• Theoretical minimum risk exposure distribution (TMRED): The prevalence of a risk factor that would confer minimal risk of the outcome on a population (e.g., SBP 114 mmHg).

 Population-attributable fraction (PAF): The proportion of the total burden of a condition estimated to be causally related to the exposure of a population to a risk factor





Percentage of DALYs attributable to risk factors by pathological type of stroke for both sexes combined



# Years of life lost (YLLs)

- YLLs = (number of deaths due to the condition at each age) x (life expectancy at the age at which death occurs)
- Years of life lost due to premature mortality. Example: YLLs due to stroke in Canada in 2019 was over 232,000. It means that 232,000 years of life was lost in Canada due to stroke in 2019
- It reflects a <u>fatal</u> burden of the condition

# National age-standardised YLL rates for all neurological conditions combined, 2021



Years lived with disability (YLD)

- YLD = (number of prevalent cases of the condition) x (disability weights for the condition) x (average duration of the condition in years until death)
- This includes health loss that may last for only a few days or for a lifetime. For example, YLD due to stroke in Canada in 2019 was almost 97,000. It means that 97,000 years of full health were lost in Canada in 2019 due to stroke.
- It reflects a <u>non-fatal</u> burden of the condition

# National age-standardised YLD rates for all neurological conditions combined, 2021



# Disability weights

- An estimate of the severity of a health state, measured on a 0–1 scale, where 0 represents no health loss and 1 represents complete health loss (death)
- Derived from a worldwide, cross-cultural study to compare the relative severity of health problems

# Example of GBD disability weights for selected sequelae of stroke and dementia

Condition	Health state lay description	Disability Weight (95% UI)
Stroke, mild	This person has some difficulty in moving around and some weakness in one hand but is able to walk without help.	0.019 (0.010–0.032)
Stroke, moderate, with no heart failure	This person has some difficulty in moving around and in using the hands for lifting and holding things, dressing, and grooming.	0.070 (0.046–0.099)
Stroke, severe, with no heart failure	Is confined to bed or a wheelchair, has difficulty speaking, and depends on others for feeding, toileting, and dressing.	0.552 (0.377–0.707)
Dementia, mild	This person has some trouble remembering recent events and finds it hard to concentrate and make decisions and plans. They may have slight to moderate difficulty engaging in community affairs, complicated hobbies, and intellectual interests.	0.069 (0.046–0.099)
Dementia, moderate	This person retains highly learned material, but has severe memory problems, is disoriented with respect to time and sometimes place. They are severely impaired in their ability to handle problems and make social judgements. They require assistance with daily activities, and only retain simple chores and hobbies.	0.377 (0.252–0.508)

Disabilityadjusted life years (DALYs) lost

- DALYs Years of healthy life lost to premature death and disability
- **DALYs** = YLL + YLD

# National age-standardised DALY rates for all neurological conditions, 2021



# Three diseases contributing most to the global burden of neurological conditions, and % of change from 1990 to 2021 (highlighted)



# **Top 10 neurological** disorders in the world by 21 GBD regions





Western sub-Saharan Africa

## Sociodemographic Index (SDI)

 A summary measure that identifies where countries or other geographic areas sit on the spectrum of development. Expressed on a scale of 0 to 1, SDI is a composite average of the rankings of the incomes per capita, average educational attainment, and fertility rates of all areas in the GBD study.

Age-standardised DALY rates trend of all neurological disorders combined by SDI



### Understanding GBD 1990-2021 Study limitations

- Not all common neurological disorders were included (e.g., diabetic neuropathy, restless leg syndrome etc.)
- Not all types of mental disorders included into the group of neurodevelopmental disorders
- Not the whole spectrum of neurological complications associated with COVID-19 was included
- We assumed independence of disabling sequelae when making comorbidity corrections, which can lead to overestimation of the nonfatal burden
- Did not account for deaths associated with TBI and SCI
- General limitations shared by all GBD studies

Understanding differences in the same estimates between cycles of GBD publications

### **Causes of differences**

- Implementation of methodological improvements
- Incorporation of new evidence and data (including additional health conditions)

### Interpretation of difference

• Latest published estimates overwrite previously published estimates for all previous years

